Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirepemat SCHEMBL30149941 | 0.87 | HDAC4 (0.36) | SLC6A2SLC6A4SLC6A3HDAC4HTR1A | |
| Pirepemat SCHEMBL30149945 | 0.87 | HDAC4 (0.36) | SLC6A2SLC6A4SLC6A3HDAC4HTR1A | |
| Pirepemat SCHEMBL20563768 | 0.87 | HDAC4 (0.36) | SLC6A2SLC6A4SLC6A3HDAC4HTR1A | |
| Pirepemat SCHEMBL30149946 | 0.87 | HDAC4 (0.36) | SLC6A2SLC6A4SLC6A3HDAC4HTR1A | |
| Pirepemat SCHEMBL2421535 | 0.87 | HDAC4 (0.36) | SLC6A2SLC6A4SLC6A3HDAC4HTR1A | |
| Pirepemat SCHEMBL28355846 | 0.80 | HDAC4 (0.40) | SLC6A2SLC6A4SLC6A3HDAC4 | |
| Pirepemat SCHEMBL28959986 | 0.80 | HDAC4 (0.37) | SLC6A2SLC6A4SLC6A3HDAC4 | |
| Pirepemat SCHEMBL28883051 | 0.77 | HDAC4 (0.38) | SLC6A2SLC6A4SLC6A3HDAC4ATM | |
| SCHEMBL1329710 | 0.74 | HDAC4 (0.33) | HDAC4 | |
| SCHEMBL1329573 | 0.73 | HDAC4 (0.42) | SLC6A2SLC6A4SLC6A3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586572-B2 | 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2013-11-19 | — | — | US | claimed |
| US-20110281835-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-11-17 | — | — | US | claimed |
| EP-2367785-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | claimed |
| WO-2010058017-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | claimed |
| EP-2367785-B1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8586572-B2 | 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2013-11-19 | — | — | US | disclosed |
| US-20110281835-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-11-17 | — | — | US | disclosed |
| EP-2367785-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010058017-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281835-A1 | NOVEL 3-PHENYL-AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 40/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.